Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of polymorphism of the beta(1) adrenoreceptor and CYP2D6 on the therapeutic effects of metoprolol.

The Journal of international medical research - 1 Jan 2000

Yuan H, Huang Z, Yang G, Lv H, Sang H, Yao Y

Abstract excerpt

Metoprolol is a lipophilic beta(1) selective adrenergic receptor antagonist used in antihypertensive therapy. It is metabolized by the protein product of the cytochrome P450 2D6 (CYP2D6) gene. Few studies have been performed on the association between the beta(1) adrenoreceptor, CYP2D6 polymorphi...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antihypertensive Agents
Share to Blood Pressure
Share to Cytochrome P-450 CYP2D6

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dose-Response Relationship, Drug

Share to Heart Rate

Share to Hypertension

Share to Metoprolol

Share to Receptors, Adrenergic, beta-1

Source

Identifiers

PMID: 19094446
DOI: 10.1177/147323000803600624

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19094446-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of polymorphism of the beta(1) adrenoreceptor and CYP2D6 on the therapeutic effects of metoprolol.PMID 19094446Read ↗

The pharmacogenetics of β-adrenergic receptor antagonists in the treatment of hypertension and heart failure.Semantic proximity Read ↗

CYP2D6 polymorphism and its impact on the clinical response to metoprolol: A systematic review and meta-analysis.Semantic proximity Read ↗

Han Chinese specific cytochrome P450 polymorphisms and their impact on the metabolism of anti-hypertensive drugs with adrenoreceptor blocking properties.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy.Semantic proximity Read ↗

Impact of CYP2D6 Genetic Variation on the Response of the Cardiovascular Patient to Carvedilol and Metoprolol.Semantic proximity Read ↗

Physiologically based pharmacokinetic modelling to predict the pharmacokinetics of metoprolol in different CYP2D6 genotypes.Semantic proximity Read ↗

Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users.Semantic proximity Read ↗

Impact of CYP2D6 Polymorphisms on Clinical Efficacy and Tolerability of Metoprolol TartrateSemantic proximity Read ↗

Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics.Semantic proximity Read ↗

Pharmacogenetic polymorphisms affecting bisoprolol response.Semantic proximity Read ↗

Impact of genotype-predicted CYP2D6 metabolism on clinical effects and tolerability of metoprolol in patients after myocardial infarction - a prospective observational study.Semantic proximity Read ↗

Genetic variation, β-blockers, and perioperative myocardial infarction.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.